Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 210 | 45 | 154 |
| Samples | 203 | 43 | 150 |
| Peptides | 174 | 39 | 132 |
Function
ZIC2 · Zic family zinc finger 2
This gene encodes a member of the ZIC family of C2H2-type zinc finger proteins. This protein functions as a transcriptional repressor and may regulate tissue specific expression of dopamine receptor D1. Expansion of an alanine repeat in the C-terminus of the encoded protein and other mutations in this gene cause holoprosencephaly type 5. Holoprosencephaly is the most common structural anomaly of the human brain. A polyhistidine tract polymorphism in this gene may be associated with increased risk of neural tube defects. This gene is closely linked to a gene encoding zinc finger protein of the cerebellum 5, a related family member on chromosome 13. [provided by RefSeq, Jul 2016].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000376335 | O95409 | 210 | 174 |
Gene Properties
Recurrent Mutations
All 174 amino-acid changes on canonical ENST00000376335 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ZIC2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ZIC2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 6/612 1% |
| Gastric Carcinoma | 0/74 0% | 23/1809 1% |
| Thyroid Gland Carcinoma | 3/45 7% | 16/1592 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Melanoma | 1/210 0% | 13/1899 1% |
| Other Sarcomas | 0/69 0% | 5/699 1% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Colorectal Carcinoma | 6/143 4% | 13/3239 0% |
| Head and Neck Carcinoma | 1/85 1% | 8/1574 1% |
| Other Solid Cancers | 3/94 3% | 5/1515 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 6/1390 0% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Esophageal Carcinoma | 1/23 4% | 2/769 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 2/810 0% |
| Non-Cancerous | 1/104 1% | 2/830 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Neuroblastoma | 2/87 2% | 1/1331 0% |
| Kidney Carcinoma | 1/85 1% | 3/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 3/2534 0% |
Mutation Distribution
Where ZIC2 is mutated · all tissues, split by cell line vs tissue
How many mutations in ZIC2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 50 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 210 mutations in ZIC2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|